IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY. (June 2017) - Rule, S.; Jurczak, W.; Jerkeman, M.; Santucci Silva, R.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens‐Harig, M.; Hess, G.; Bence‐Bruckler, I.; et al.